Amal F Gharib1, Amany Salah Khalifa2, Emad Mohamed Eed3, Hamsa Jameel Banjer1, Ashjan Ali Shami1, Ahmad El Askary1, Wael H Elsawy4. 1. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia. 2. Clinical Pathology and Pharmaceutics Department, Faculty of Pharmacy, Taif University, Taif, Kingdom of Saudi Arabia. 3. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia; dremadeed@yahoo.com. 4. Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Abstract
BACKGROUND/AIM: Breast cancer (BC) is among the most widespread malignant tumors in women. In the current study, we evaluated the role of miR-31 in BC patients and its relation to the different prognostic, clinical, and pathological features. PATIENTS AND METHODS: MiR-31 levels were determined by RT-PCR in BC and adjacent normal breast tissues from 100 BC patients. BC diagnosis was established through histopathological examinations. The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) receptor in all tumors was determined using immunohistochemistry. RESULTS: MiR-31 expression was reduced in BC tissues relative to adjacent healthy breast tissue (mean levels were 0.93 and 7.2, respectively). Also, the low expression of miR-31 in BC patients was significantly correlated with adverse clinical and pathological features such as: young patient's age, premenopausal status, infiltrative lobular carcinoma, ER and PR negative tumors, HER2 positive tumors, and advanced clinical stage. CONCLUSION: MiR-31 was expressed at low levels in BC tissues and correlated with adverse clinical and pathological features, and poor survival.
BACKGROUND/AIM: Breast cancer (BC) is among the most widespread malignant tumors in women. In the current study, we evaluated the role of miR-31 in BC patients and its relation to the different prognostic, clinical, and pathological features. PATIENTS AND METHODS: MiR-31 levels were determined by RT-PCR in BC and adjacent normal breast tissues from 100 BC patients. BC diagnosis was established through histopathological examinations. The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) receptor in all tumors was determined using immunohistochemistry. RESULTS: MiR-31 expression was reduced in BC tissues relative to adjacent healthy breast tissue (mean levels were 0.93 and 7.2, respectively). Also, the low expression of miR-31 in BC patients was significantly correlated with adverse clinical and pathological features such as: young patient's age, premenopausal status, infiltrative lobular carcinoma, ER and PR negative tumors, HER2 positive tumors, and advanced clinical stage. CONCLUSION: MiR-31 was expressed at low levels in BC tissues and correlated with adverse clinical and pathological features, and poor survival.
Authors: Igor Kiss; Jitka Mlcochova; Zbynek Bortlicek; Alexandr Poprach; Jiri Drabek; Petra Vychytilova-Faltejskova; Marek Svoboda; Tomas Buchler; Stanislav Batko; Ales Ryska; Marian Hajduch; Ondrej Slaby Journal: Anticancer Res Date: 2016-09 Impact factor: 2.480
Authors: Kimberly H Allison; M Elizabeth H Hammond; Mitchell Dowsett; Shannon E McKernin; Lisa A Carey; Patrick L Fitzgibbons; Daniel F Hayes; Sunil R Lakhani; Mariana Chavez-MacGregor; Jane Perlmutter; Charles M Perou; Meredith M Regan; David L Rimm; W Fraser Symmans; Emina E Torlakovic; Leticia Varella; Giuseppe Viale; Tracey F Weisberg; Lisa M McShane; Antonio C Wolff Journal: Arch Pathol Lab Med Date: 2020-01-13 Impact factor: 5.534
Authors: Xi Liu; Lorenzo F Sempere; Haoxu Ouyang; Vincent A Memoli; Angeline S Andrew; Yue Luo; Eugene Demidenko; Murray Korc; Wei Shi; Meir Preis; Konstantin H Dragnev; Hua Li; James Direnzo; Mads Bak; Sarah J Freemantle; Sakari Kauppinen; Ethan Dmitrovsky Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Annika Schaefer; Monika Jung; Hans-Joachim Mollenkopf; Ina Wagner; Carsten Stephan; Florian Jentzmik; Kurt Miller; Michael Lein; Glen Kristiansen; Klaus Jung Journal: Int J Cancer Date: 2010-03-01 Impact factor: 7.396